Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Roche has ended its collaboration with UCB on Alzheimer's treatments, marking the third candidate dropped by Roche this year. Meanwhile, activist investor Starboard has set its sights on Kenvue, a division of J&J, following its $1 billion stake in Pfizer. In other news, the FDA has rejected Camurus' treatment for a rare hormonal disorder due to manufacturing is...